CIS Pharma attends EMSO sarcoma symposium in Milano
Milano, Italy, Monday February 3 to Wednesday February 5, 2020 - CIS Pharma attends the sarcoma symposium of the European Society for Medical Oncology, EMSO, in Milano. The event is [...]
CIS Pharma team attends the World Economic Forum in Davos
Davos, Switzerland, Thursday, January 23, 2020 – CIS Pharma attends the World Economic Forum in Davos, Switzerland. The main interest is to meet with its tracking technology partner modum.io and [...]
CIS Pharma’s polymer-drug carriers successfully loaded with Lu-177 and In-111
Bubendorf, Switzerland, Wednesday, January 8, 2020 - In several laoding experiments Lutetium-177 and Indium-111 were loaded to CIS Pharma’s polymer-drug carriers, at high efficiency reates. Labeling density was close the [...]
CIS Pharma PEEK implant program has reached the first milestone
Bubendorf, Switzerland, Thursday, December 12, 2019 - A new method for the modification of PEEK surfaces was established that significantly increases hydrophilicity of the material surface. The novel method is [...]
CIS Pharma’s polymer-drug carriers to load radioisotopes show excellent performance in a multiparameter toxicity study
Bubendorf, Switzerland, Monday, December 9, 2019 - CIS Pharm has tested several of its new polymer-drug carriers to conjugate radionuclides in a multiparameter cytotoxicity study at Cyprotex, a CRO based [...]
CIS Pharma Christmas event in Arlesheim on ice
Arlesheim, Switzerland, Friday, December 6, 2019 - The team of CIS Pharma sets out on sheer ice, armed with stone and broom. After a short introduction, we are ready to play [...]
CIS Pharma team attends Asia-Pacific vitreo-retina society congress
Shanghai, China, Friday, November 22, 2019 – CIS Pharma is attending the Asia-Pacific vitreo-retina society congress in Shanghai to meet potential partners for its technologies in eye care during the [...]
CIS Pharma successfully conjugated a model antibody to its polymer-drug carrier comprising radioisotopes
Bubendorf, Switzerland, Friday, November 1, 2019 - Within the scope of the proof-of-concept study at the Paul Scherer Institute, a number of polymer-drug carriers enabling the conjugation of different amounts [...]
CIS Pharma and the University of Appplied Sciences present their bio-membrane project at the Nano-Tech Event in Baden
Baden, Switzerland, Tuesday, October 29, 2019 - CIS Pharma and the University of Applied Sciences, FHNW Muttenz, are giving a talk at the Nano-Tech Apèro of the Swiss Nanoscience Institute, [...]
Actinium announces positive interim results of antibody-radionuclide conjugate Iomab-B pivotal trial
New York, USA, Monday, October 28, 2019 - Actinium Pharmaceuticals Inc. announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, an antibody-radionuclide conjugate, including feasibility and [...]